Phaseline

Targets › GLP1R

GLP1R (Glucagon-like peptide 1 receptor): drug programs, companies and trials

77 programs from 60 companies in 620 trials: 186 Phase 2, 174 Phase 3, 136 Phase 1, 124 Phase 4; Metabolic and endocrine, Cardiovascular, Immunology; next expected readout Nov 2026.

G protein-coupled receptor for glucagon-like peptide 1 (GLP-1). Ligand binding triggers activation of a signaling cascade that leads to the activation of adenylyl cyclase and increased intracellular cAMP levels. (UniProt, P43220)

Open in Phaseline: the race on GLP1R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mayo ClinicBCG Solution
Glucagon-like peptide 1 receptor agonist
GLP1R, Ion channels, CD38, OPRM1, PDCD1, CD274Phase 4Pain, Postoperative; Limb Pain, Phantom; Healthy; Respiratory Function Loss …Nov 2026
Brigham and Women's HospitalMIB 626 (NMN)
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2CPhase 4Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension …Nov 2026
Eli LillyTirzepatide (LY3298176)
Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist
GIPR, GLP1RPhase 4Diabetes Mellitus, Type 2; Psoriatic Arthritis; Type 2 Diabetes; Psoriasis …Nov 2026
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolEfsubaglutide Alfa Injection
GLP-1 receptor agonist
GLP1RPhase 4ObesityNov 2026
Novo NordiskSemaglutide
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 4Obesity; Cardiovascular Risk; Cardiovascular Disease; Diabetes Mellitus, Type 2 …Dec 2026
Children's Hospital Medical Center, CincinnatiGLP-1 agonist
GLP-1 receptor agonist
GLP1RPhase 4Diabetes Mellitus, Type 2Dec 2026
Odense University HospitalCapsule FMT
Amiloride-sensitive sodium channel, ENaC blocker
GLP1R, ATP4A, ATP4B, CTLA4, FKBP1A, TNF, PDCD1, SCNN1A, SCNN1B, SCNN1GPhase 4Gastroesophageal Reflux; Colitis; Chronic Kidney Disease(CKD); Postmenopausal Women …Dec 2026
Maisa N. Feghali, MDExenatide
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 4Gestational DiabetesDec 2026
Medical College of WisconsinGLP-1 agonists
GLP-1 receptor agonist
GLP1RPhase 4Psoriatic Arthritis (PsA)Oct 2027
China National Center for Cardiovascular DiseasesMazdutide
Dual GLP-1/glucagon receptor agonist
GLP1R, GCGRPhase 4Obesity & OverweightDec 2027
Hangzhou Zhongmei Huadong Pharmaceuticalliraglutide
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 4T2DM (Type 2 Diabetes Mellitus)Dec 2027
University of Missouri-ColumbiaGLP-1 receptor agonist
GLP-1 receptor agonist
GLP1RPhase 4Morbid ObesityJul 2028
West China HospitalMazdutide
GLP-1/GCG receptor dual agonist
GLP1R, GCGRPhase 4Metabolic Dysfunction-Associated SteatohepatitisFeb 2029
Green Valley (Shanghai) PharmaceuticalsSodium Oligomannate Capsules (GV-971)
Modulator of gut microbiota and neuroinflammation
GLP1R, FFAR2Phase 4Alzheimer Disease; Alzheimer's DiseaseJun 2029
The Cleveland ClinicGLP-1 or GIP-based therapy
GLP-1 receptor agonist and/or GIP receptor agonist
GLP1R, GIPRPhase 4GLP - 1–
Gan & Lee Pharmaceuticals.GZR4
GLP-1 receptor agonist
GLP1RPhase 3DiabetesNov 2026
AmgenMaridebart cafraglutide (AMG 133)
GLP-1 receptor agonist and GIP receptor agonist (dual GLP-1/GIP receptor agonist)
GLP1R, GIPRPhase 3Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight; Obesity; Obesity Disease; Obstructive Sleep Apnea …Nov 2026
Eli LillyBrenipatide (LY3537031)
GLP-1 receptor agonist
GLP1RPhase 3Depressive Disorder, Major; Alcohol Use Disorder; Smoking; Irritable Bowel Syndrome …Nov 2026
Hangzhou Zhongmei Huadong PharmaceuticalHDM1005 injection
GLP-1 receptor agonist
GLP1RPhase 3Obesity & Overweight; Type 2 Diabetes; Obesity; Overweight and/or ObesityNov 2026
Eli LillyRetatrutide
Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist
GCGR, GLP1R, GIPRPhase 3Obesity; Type 2 Diabetes; Diabetes Mellitus, Type 2; Atherosclerotic Cardiovascular Disease (ASCVD) …Nov 2026
Beijing Dongfang BiotechJY09 (1.2mg)
Exendin-4 Fc fusion protein; GLP-1 receptor agonist
GLP1RPhase 3Type 2 Diabetes Mellitus; Type2 Diabetes MellitusNov 2026
Beijing QL BiopharmaceuticalZovaglutide (ZT002 Injection)
GLP-1 receptor agonist
GLP1RPhase 3Overweight , Obesity; Overweight,Obesity; Overweight, ObesityDec 2026
Boehringer IngelheimSurvodutide
Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist
GLP1R, GCGRPhase 3Type 2 Diabetes; Metabolic Dysfunction Associated Steatohepatitis; Metabolic Dysfunction Associated Steatohepatitis (MASH); Healthy …Dec 2026
Novo NordiskLiraglutide
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 3Obesity; Type 2 Diabetes Patients; Atrial Fibrillation; Severe Obesity …Dec 2026
Eli LillyEloralintide (LY3841136)
GLP-1/GCG dual receptor agonist
GLP1R, GCGRPhase 3Overweight; Obesity; Sleep Apnea, Obstructive; Osteoarthritis …Dec 2026
Fujian Shengdi PharmaceuticalHRS9531 Injection
GLP-1 receptor agonist
GLP1RPhase 3Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy; Bstructive Sleep Apnea (OSA) and Obesity; Type 2 Diabetes; Obesity …Dec 2026
Innovent Biologics (Suzhou)IBI362
GLP-1 receptor agonist
GLP1RPhase 3Overweight; Sleep Apnea; Adolescents With Obesity or Overweight With Weight-Related Comorbidities; Obesity …Dec 2026
Novo NordiskCagrilintide B
Dual GLP-1/glucagon receptor agonist
GLP1R, GCG, CALCRPhase 3Obesity; Overweight; Cardiovascular Disease; Diabetes Mellitus, Type 2Jan 2027
PfizerBerobenatide (PF-08653944, MET097)
Dual GLP-1R/GIPR agonist
GIPR, GLP1RPhase 3Obesity and Overweight; Obesity; Apnea; Overweight …Jan 2027
Amylyx PharmaceuticalsAvexitide
Glucagon-like peptide 1 receptor antagonist
GLP1RPhase 3Post Bariatric HypoglycemiaFeb 2027
Eli LillyOrforglipron (LY3502970)
GLP-1 receptor agonist
GLP1RPhase 3Obesity; Diabetes Mellitus, Type 2; Hypertension; Urinary Incontinence,Stress …Feb 2027
Hangzhou Sciwind BiosciencesXW003 injection
GLP-1 receptor agonist
GLP1RPhase 3OSA - Obstructive Sleep Apnea; ObesityFeb 2027
RocheEnicepatide (RO7795068)
Dual GLP-1/GIP receptor agonist
GLP1R, GIPRPhase 3Obesity; Obesity or Overweight; Healthy ParticipantsApr 2027
KaileraRibupatide (KAI-9531)
GLP-1 receptor agonist
GLP1RPhase 3Obesity; Obesity With Diabetes; End Stage Renal DiseaseMay 2027
Viking TherapeuticsVK2735
GLP-1 and GIP dual agonist
GLP1R, GIPRPhase 3Weight Loss; Obese AdultsMay 2027
Novo NordiskCagriSema
Amylin and GLP-1 receptor agonist combination
GLP1R, CALCRPhase 3Obesity; Diabetes Mellitus, Type 2; OverweightJun 2027
Chendu DIAO Pharmaceutical GroupDA-302168S
GLP-1R agonist
GLP1RPhase 3Overweight and ObesityJul 2027
AltimmunePemvidutide
GLP-1 and glucagon receptor dual agonist
GLP1R, GCGRPhase 3Metabolic Dysfunction-Associated Steatohepatitis (MASH); Alcohol-associated Liver DiseaseSep 2027
Hanmi Pharmaceutical CompanyEfpeglenatide
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 3Type 2 DiabetesNov 2027
Eli LillyDulaglutide (LY2189265)
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 3Type 2 Diabetes; Myocardial Injury; Cystic Fibrosis; Diabetes Mellitus, Type 1 …Dec 2027
Hangzhou Sciwind BiosciencesEconoglutide Injection
GLP-1 receptor agonist
GLP1RPhase 3Knee OsteoarthritisMay 2028
Novo NordiskZenagamtide
GLP-1/GIP receptor agonist
GLP1R, GIPRPhase 3Overweight; Type 2 DiabetesJun 2028
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeuticsaleniglipron
GLP-1 receptor agonist
GLP1RPhase 3Obesity; Obesity, Overweight, or Chronic Weight Management; ObeseSep 2028
RochePetrelintide
Dual GLP-1 and glucagon receptor agonist
GLP1R, GCGRPhase 3Obesity or OverweightOct 2028
Fu Jen Catholic University HospitalGLP-1 receptor agonists (long-acting)
GLP-1 receptor agonist
GLP1RPhase 3GLP-1Jun 2029
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolMazdutide (IBI362)
Triple GLP-1/GIP/glucagon receptor agonist
GLP1R, GIPR, GCGRPhase 3Dementia, MildAug 2029
Seattle Children's HospitalExenatide
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 3Childhood Obesity–
Nanjing First Hospital, Nanjing Medical UniversityGLP-1RA
GLP-1 receptor agonist
GLP1RPhase 3Type 2 Diabetes Mellitus–
Regeneron PharmaceuticalsOlatorepatide (HS-20094)
GLP-1 and GIP receptor agonist
GLP1R, GIPRPhase 2Overweight or ObesityNov 2026
Eli LillyLY3938577
GLP-1 receptor agonist
GLP1RPhase 2Diabetes Mellitus, Type 2Nov 2026
Shanghai Minwei BiotechnologyMWN109 2
GLP-1 receptor agonist
GLP1RPhase 2Overweight , Obesity; Type 2 Diabetes Mellitus (T2DM); Overweight or Obese; Overweight or ObesityNov 2026
RocheRO7795081
GLP-1/GIP receptor dual agonist
GIPR, GLP1RPhase 2Type 2 Diabetes Mellitus; Overweight; Healthy Volunteers; Renal ImpairmentDec 2026
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Efsubaglutide Alfa
GLP-1 receptor agonist
GLP1RPhase 2Obesity and Overweight; Adolescence ObesityDec 2026
AstraZenecaAZD6234 in combination with AZD9550
Dual GCG and GLP-1 receptor agonist
GCG, GLP1RPhase 2Obesity/Overweight; Healthy Participants; Overweight and Obesity; Hepatic ImpairmentJan 2027
NovartisJSB462 (luxdegalutamide)
GLP-1 receptor agonist
GLP1RPhase 2Prostatic Cancer, Castration-Resistant; Metastatic Hormone-sensitive Prostate Cancer; Metastatic Prostate Cancer (mCRPC); Progressive Metastatic Castrate Resistant Prostate CancerJan 2027
Hudson BiotechRetatrutide (LY3437943)
Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist
GCGR, GLP1R, GIPRPhase 2ObesityMar 2027
Sun Pharmaceutical IndustriesGL0034
GLP-1 receptor agonist
GLP1RPhase 2Type II Diabetes MellitusApr 2027
Chinese University of Hong KongGLP-1 receptor agonist
GLP-1 receptor agonist
GLP1RPhase 2Cerebral Small Vessel DiseaseMay 2027
Shanghai Zhongshan HospitalHEC88473
GLP-1/FGF21 dual agonist
GLP1R, FGFR1Phase 2PCOS (Polycystic Ovary Syndrome)Jun 2027
Hanmi Pharmaceutical CompanyHM15912 (sonefpeglutide)
GLP-1 receptor agonist
GLP1RPhase 2Short Bowel SyndromeDec 2027
Verdiva Bio DevVRB-101 (Ecnoglutide)
GLP-1 receptor agonist
GLP1RPhase 2ObesityMar 2028
University of VirginiaGLP-1 receptor agonist
GLP-1 receptor agonist
GLP1RPhase 2Obesity in ChildrenFeb 2030
University Hospital, Gentofte, CopenhagenDapiglutide
Dual GLP-1R/GLP-2R agonist
GLP1R, GLP2RPhase 2Obesity–
Durham VA Medical CenterGLP-1 receptor agonist
GLP-1 receptor agonist - once weekly injectable; mimics effects of Roux-en-Y gastric bypas
GLP1RPhase 2Type 2 Diabetes–
4Moving BiotechLiraglutide
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 2Knee Osteoarthritis–
Daewoong PharmaceuticalDWRX5003
GLP-1 receptor agonist delivered via microneedle patch
GLP1RPhase 1Obesity & OverweightNov 2026
Merck & Co. (MSD)MK-4082
GLP-1 receptor agonist
GLP1RPhase 1HealthyDec 2026
Chia Tai Tianqing Pharmaceutical GroupTQF3250 capsules
glucagon-like peptide-1 receptor agonist
GLP1RPhase 1Hyperglycemia; Overweight/Obesity; Type 2 Diabetes Mellitus Combined With Overweight or ObesityDec 2026
Hangzhou Sciwind Biosciencesecnoglutide tablets
GLP-1 receptor agonist
GLP1RPhase 1Overweight and/or ObesityJan 2027
Terrestrial BioVX-201
GLP-1 receptor agonist delivered via microneedle array patch
GLP1RPhase 1Overweight and/or ObesityFeb 2027
Yale UniversityGLP-1 analogue
GLP-1 receptor agonist
GLP1RPhase 1type1diabetesAug 2027
David D'Alessio, M.D.Exendin-9
Competitive antagonist of the GLP-1 receptor
GLP1RPhase 1Diabetes (DM)Dec 2027
China-Japan Friendship HospitalGLP-1 Receptor Agonists
GLP-1 receptor agonist
GLP1RPhase 1ObesityDec 2027
Mapi PharmaSG Depot 2 mg
GLP-1 receptor agonist
GLP1RPhase 1Diabete Type 2May 2028
BiolingusLiraglutide
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 1Diabete Type 2–
Shanghai World Leader PharmaceuticalSemaglutide (WL1006)
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 1Overweight–
Shanghai Xitaili Biomedicine TechnologyXTL6001
triple-target GLP-1 receptor agonist
GLP1RPhase 1Weight Management in Adult Patients With Obesity or Overweight–

Conditions

Obesity (110) Overweight (26) Diabetes Mellitus, Type 2 (17) Type 2 Diabetes (16) Healthy (9) Obesity or Overweight (6) Type 2 Diabetes Mellitus (6) Obesity and Obesity-related Medical Conditions (6) Alcohol Use Disorder (6) Type 1 Diabetes (6) Obstructive Sleep Apnea (5) Diabetes (5)

Modalities

protein or peptide (36), small molecule (29), mixed (9)

Companies

Eli Lilly (7) Novo Nordisk (5) Roche (3) Hangzhou Sciwind Biosciences (3) The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (2) Hangzhou Zhongmei Huadong Pharmaceutical (2) Hanmi Pharmaceutical Company (2) AstraZeneca (1) Amgen (1) Regeneron Pharmaceuticals (1) Green Valley (Shanghai) Pharmaceuticals (1) Innovent Biologics (Suzhou) (1) Daewoong Pharmaceutical (1) Fujian Shengdi Pharmaceutical (1) Boehringer Ingelheim (1) Beijing QL Biopharmaceutical (1) Pfizer (1) Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics (1) Shanghai Minwei Biotechnology (1) Nanjing First Hospital, Nanjing Medical University (1)

Related targets

GIPR (12) GCGR (9) GCG (2) CALCR (2) OPRM1 (2) PDCD1 (2) FFAR2 (1) GLP2R (1) FGFR1 (1) SLC5A2 (1) SLC6A2 (1) UNKNOWN (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.